Pressmeddelande -
Trastuzumab Deruxtecan Continues to Demonstrate Durable Responses with New Data from DESTINY-Breast01 in HER2 Positive Metastatic Breast Cancer
Trastuzumab Deruxtecan Continues to Demonstrate Durable Responses with New Data from DESTINY-Breast01 in HER2 Positive Metastatic Breast Cancer
Median duration of response exceeded 20 months
Updates show encouraging landmark survival in exploratory analysis with an estimated three out of four patients alive at 18 months
Tokyo, Munich and Basking Ridge, NJ – (December 10, 2020) – Updated results fromthe positive phase 2 DESTINY-Breast01 trial show Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and AstraZeneca's trastuzumab deruxtecan continued to demonstrate efficacy and durable responses in patients with HER2 positive metastatic breast cancer following two or more prior HER2 based regimens. These data were presented in a Spotlight Poster Discussion at the 2020 San Antonio Breast Cancer Symposium.
Ämnen
- Hälsa, sjukvård, läkemedel
Kategorier
- cancer
- onkologi
- research
- oncology
- breast cancer
Daiichi Sankyo is a global pharmaceutical company with corporate origins in Japan. We provide innovative products and services in more than 20 countries around the world. With more than 100 years of scientific expertise, our company draws upon a rich legacy of innovation and a robust pipeline of promising new medicines to help patients.
Through the outstanding knowledge and commitment of our 15,000 employees worldwide, we create innovative new and generic medicines, and new methods of drug discovery and delivery. We share a passion for innovation, as well as compassion for the patients around the world who are in need of our medicines.
